Patient preferences for eye drop characteristics - A willingness-to-pay analysis

被引:54
作者
Jampel, HD
Schwartz, GF
Robin, AL
Abrams, DA
Johnson, E
Miller, RB
机构
[1] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA
关键词
D O I
10.1001/archopht.121.4.540
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To determine the importance that patients place on the characteristics of topical therapy for lowering intraocular pressure. Methods: We administered a willingness-to-pay instrument to 230 patients from 4 glaucoma subspecialty practices, asking them how much they would be wilting to pay to obtain particular characteristics in an eye drop. Data about the subjects' demographics, economic status, attitudes toward eve drops and systemic medications, and symptoms from eye drops were correlated with their willingness to pay using 2-part models. Results: Of our subjects, 169 (77%) were using eve drops to lower their intraocular pressure. Fatigue, blurred vision, and tearing were the most commonly reported symptoms. Eye drop medications most valued by the subjects did not produce blurring, drowsiness, or inhibition of sexual performance; 85%) were willing to pay more for an eye drop that did not cause blurring, and on average the), were willing to pay 40% more. Higher educational levels and income were generally associated with a willingness to pay more for eye drops With desirable attributes. Main Outcome Measure: Willingness to pay more (in dollars). Conclusions: Patient preferences for eye drop characteristics can be assessed using a willingness-to-pay instrument. Patients place differing value on various eye drop characteristics. A better understanding of patient preference Could lead to better compliance. Arch Ophthalmol. 2003:121:540-546.
引用
收藏
页码:540 / 546
页数:7
相关论文
共 14 条
[1]   RISK REDUCTION FROM LOW OSMOLALITY CONTRAST-MEDIA - WHAT DO PATIENTS THINK IT IS WORTH [J].
APPEL, LJ ;
STEINBERG, EP ;
POWE, NR ;
ANDERSON, GF ;
DWYER, SA ;
FADEN, RR .
MEDICAL CARE, 1990, 28 (04) :324-337
[2]   Measuring heart patients' willingness to pay for changes in angina symptoms [J].
Chestnut, LG ;
Keller, MLR ;
Lambert, WE ;
Rowe, RD .
MEDICAL DECISION MAKING, 1996, 16 (01) :65-77
[3]  
Duan N, 2002, J BUS ECON STAT, V1, P115
[4]  
FURLONG W, 1990, CHEPA WORKING PAPER, V9099, P1
[5]   PROGRESSION OF VISUAL-FIELD DEFECTS IN GLAUCOMA - RELATION TO COMPLIANCE WITH PILOCARPINE THERAPY [J].
GRANSTROM, PA .
ARCHIVES OF OPHTHALMOLOGY, 1985, 103 (04) :529-531
[6]   TREATMENT FOR GLAUCOMA - ADHERENCE BY THE ELDERLY [J].
GURWITZ, JH ;
GLYNN, RJ ;
MONANE, M ;
EVERITT, DE ;
GILDEN, D ;
SMITH, N ;
AVORN, J .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1993, 83 (05) :711-716
[7]   COMPLIANCE WITH TOPICAL PILOCARPINE TREATMENT [J].
KASS, MA ;
MELTZER, DW ;
GORDON, M ;
COOPER, D ;
GOLDBERG, J .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1986, 101 (05) :515-523
[8]  
KASS MA, 1984, ARCH OPHTHALMOL-CHIC, V102, P1550
[9]   COMPLIANCE WITH TOPICAL TIMOLOL TREATMENT [J].
KASS, MA ;
GORDON, M ;
MORLEY, RE ;
MELTZER, DW ;
GOLDBERG, JJ .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1987, 103 (02) :188-193
[10]   Compliance and viewpoint of glaucoma patients in Greece [J].
Konstas, AGP ;
Maskaleris, G ;
Gratsonidis, S ;
Sardelli, C .
EYE, 2000, 14 (5) :752-756